Optimal Care Pathways
A guide to the best cancer care: new national standards for blood cancer treatment and care.
All Australians diagnosed with blood cancer, and healthcare professionals treating blood cancer, can now access guides that set out national standards for blood cancer treatment and care.
These guides, called Optimal Care Pathways, ensure blood cancer specialists, treating hospitals, GPs, and people diagnosed with blood cancer, can access the same, nationally consistent standards that outline the high-quality care all Australians should expect to receive.
Optimal Care Pathways are now available for 13 of the more common types of blood cancer, with detailed versions available for healthcare professionals and specific guides designed to support people diagnosed with blood cancer and their loved ones.
To find the document that’s right for you, please click on the relevant link below:
Need help?
Optimal Care Pathways: For health care professionals
Designed to provide nationally consistent best practice treatment, care options and information.
Optimal Care Pathways: For patients and loved ones
To support people in Australia who are diagnosed with blood cancer, and their loved ones.
All people diagnosed with a blood cancer deserve access to the best possible treatment and care that is right for them no matter who they are or where they live.
Professor John Seymour AM, co-chair of the Blood Cancer Taskforce, Chris Tanti CEO of Leukaemia Foundation and co-chair of the Blood Cancer Taskforce, and Dr Hui-Peng Lee chair of the OCP Steering Committee discuss Optimal Care Pathways in the below video:
The blood cancer Optimal Care Pathways project is an initiative of the Blood Cancer Taskforce and was jointly led by the Australasian Leukaemia & Lymphoma Group (ALLG) and the Haematology Society of Australia and New Zealand (HSANZ), with support from the Leukaemia Foundation to deliver a total of 11 OCPs.
Blood Cancers A-Z
A
AA secondary amyloidosis
Acute lymphoblastic leukaemia ALL
Acute myeloid leukaemia AML
Acute myelomonocytic leukaemia AMML
Acute promyelocytic leukaemia APML
Afib mutated fibrinogen alpha chain amyloidosis
AL systemic amyloidosis
Amyloidosis
Aplastic anaemia AA
ATTR familial amyloidotic polyneuropathy
ATTR wild type senile amyloidosis
B
Biphenotypic leukaemia
Bisphosphonates myeloma
C
Chronic lymphocytic leukaemia CLL
Chronic myeloid leukaemia CML
H
Hairy cell leukaemia
Hodgkin lymphoma
I
IgA myeloma
IgG myeloma
J
Juvenile myelomonocytic leukaemia JMML
L
Langerhans Cell Histiocytosis LCH
Leukaemia
Light chain myeloma
Lymphocyte depleted HL
Lymphocyte rich HL
Lymphoma
M
MDS with biallelic TP53 inactivation MDS-biTP53
MDS with fibrosis
MDS with hypoplastic MDS-h
MDS with increased blasts MDS-IB1
MDS with increased blasts MDS-IB2
MDS with low blasts MDS-LB
MDS with low blasts and isolated 5q deletion MDS-5q
MDS with low blasts and SF3B1 mutation MDS-SF3B1
Mixed cellularity HL
Monoclonal gammopathy of unknown significance MGUS
MPN Chronic eosinophilic leukaemia CEL
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic neutrophilic leukaemia CNL
MPN Essential thrombocythaemia ET
MPN Polycythaemia Rubra vera PV
MPN Primary myelofibrosis MF
MPN Systemic mastocytosis SM
Multiple myeloma
Myelodysplasia Myelodysplastic neoplasms MDS
Myeloma
Myeloid sarcoma localised leukaemia
Myeloproliferative neoplasms MPN
N
NHL Adult T-Cell leukaemic ATLL
NHL Anaplastic large cell ALCL
NHL Burkitt’s
NHL Cutaneous T-Cell
NHL Diffuse large B-cell DLBCL
NHL Double hit DHL
NHL Follicular
NHL Lymphoplasmacytic Waldenstrom’s macroglobulinaemia WM
NHL MALT
NHL Mantle cell
NHL Marginal zone
NHL Peripheral T-Cell
NHL Primary cutaneous B-cell
NHL Primary mediastinal B-cell PMBCL
NHL Small lymphocytic SLL
NHL Subcutaneous panniculitis-like T-Cell
NHL T-Lymphoblastic
NHL Waldenstroms macroglobulinaemia
Non-Hodgkin lymphoma
Nodular lymphocyte predominant HL
Nodular sclerosing HL
O
Osteosclerotic myeloma
P
Paroxysmal nocturnal haemoglobinuria
Plasmacytoma localised myeloma
POEMS syndrome
R
Richter’s syndrome leukaemia
S
Smouldering indolent myeloma
Solitary plasmacytoma myeloma
Systemic mastocytosis